Get the Stockscreener App
0.4529
10.34%
-0.0521
Cyclacel Pharmaceuticals Inc stock is traded at $0.4529, with a volume of 794.13K.
It is down -10.34% in the last 24 hours and down -50.43% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
See More
Previous Close:
$0.505
Open:
$0.5045
24h Volume:
794.13K
Relative Volume:
0.78
Market Cap:
$973.39K
Revenue:
-
Net Income/Loss:
$-22.56M
P/E Ratio:
-0.2347
EPS:
-1.93
Net Cash Flow:
$-16.12M
1W Performance:
-33.42%
1M Performance:
-50.43%
6M Performance:
-77.36%
1Y Performance:
-22.07%
1-Day Range:
$0.4326
$0.5045
1-Week Range:
$0.4326
$0.686
52-Week Range:
$0.231
$4.3785
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Cyclacel Pharmaceuticals Inc (CYCC)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Metric Analysis: Cyclacel Pharmaceuticals Inc (CYCC)’s Key Ratios in the Limelight - The Dwinnex
You might want to take a look at Cyclacel Pharmaceuticals Inc (CYCC) now - SETE News
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Cyclacel Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK
Geopark Ltd, Cyclacel Pharmaceuticals, Another 3 Companies Have A High Estimated Dividend Yield - Via News Agency
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com
Cyclacel Pharmaceuticals faces Nasdaq delisting - Investing.com
Cyclacel Pharmaceuticals faces Nasdaq delisting By Investing.com - Investing.com UK
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript - MSN
Cyclacel Pharmaceuticals changes its auditor - Investing.com
Cyclacel Pharmaceuticals changes its auditor By Investing.com - Investing.com UK
Cyclacel stock hits 52-week low at $1.21 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclacel Pharmaceuticals Inc Stock (CYCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rombotis Spiro George | President and CEO |
Dec 21 '23 |
Buy |
3.31 |
6,070 |
20,122 |
68,658 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):